Selected research
Industry Research
AI Drug Design Industry Research Report 2026
Market perspective
The global AI Drug Design market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AI Drug Design market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AI Drug Design market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AI Drug Design market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AI Drug Design include Exscientia, PathAI, Tempus, Aria Pharmaceuticals, BenchSci, Antidote, AiCure, Atomwise and Envisagenics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global AI Drug Design market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AI Drug Design.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AI Drug Design Market by Company
Exscientia
PathAI
Tempus
Aria Pharmaceuticals
BenchSci
Antidote
AiCure
Atomwise
Envisagenics
Sherlock
Deep Genomics
Benevolent
Iktos
AlmirallShare
AI Drug Design Segment by Type
Therapy Research
Design and Development
Others
AI Drug Design Segment by Application
Cancer
Cardiovascular Disease
Others
AI Drug Design Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Drug Design market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Drug Design and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Drug Design.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AI Drug Design companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Therapy Research
- Design and Development
- Others
Applications
- Cancer
- Cardiovascular Disease
- Others
Companies covered
- Exscientia
- PathAI
- Tempus
- Aria Pharmaceuticals
- BenchSci
- Antidote
- AiCure
- Atomwise
- Envisagenics
- Sherlock
- Deep Genomics
- Benevolent
- Iktos
- AlmirallShare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 AI Drug Design by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Therapy Research
- 2.2.3 Design and Development
- 2.2.4 Others
- 2.3 AI Drug Design by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Cardiovascular Disease
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 AI Drug Design Breakdown Data by Type
- 3.1 Global AI Drug Design Historic Market Size by Type (2021-2026)
- 3.2 Global AI Drug Design Forecasted Market Size by Type (2027-2032)
4 AI Drug Design Breakdown Data by Application
- 4.1 Global AI Drug Design Historic Market Size by Application (2021-2026)
- 4.2 Global AI Drug Design Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global AI Drug Design Market Perspective (2021-2032)
- 5.2 Global AI Drug Design Growth Trends by Region
- 5.2.1 Global AI Drug Design Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 AI Drug Design Historic Market Size by Region (2021-2026)
- 5.2.3 AI Drug Design Forecasted Market Size by Region (2027-2032)
- 5.3 AI Drug Design Market Dynamics
- 5.3.1 AI Drug Design Industry Trends
- 5.3.2 AI Drug Design Market Drivers
- 5.3.3 AI Drug Design Market Challenges
- 5.3.4 AI Drug Design Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top AI Drug Design Players by Revenue
- 6.1.1 Global Top AI Drug Design Players by Revenue (2021-2026)
- 6.1.2 Global AI Drug Design Revenue Market Share by Players (2021-2026)
- 6.2 Global AI Drug Design Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of AI Drug Design Head Office and Area Served
- 6.4 Global AI Drug Design Players, Product Type & Application
- 6.5 Global AI Drug Design Manufacturers Established Date
- 6.6 Global AI Drug Design Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America AI Drug Design Market Size (2021-2032)
- 7.2 North America AI Drug Design Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America AI Drug Design Market Size by Country (2021-2026)
- 7.4 North America AI Drug Design Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe AI Drug Design Market Size (2021-2032)
- 8.2 Europe AI Drug Design Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe AI Drug Design Market Size by Country (2021-2026)
- 8.4 Europe AI Drug Design Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific AI Drug Design Market Size (2021-2032)
- 9.2 Asia-Pacific AI Drug Design Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific AI Drug Design Market Size by Country (2021-2026)
- 9.4 Asia-Pacific AI Drug Design Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America AI Drug Design Market Size (2021-2032)
- 10.2 South America AI Drug Design Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America AI Drug Design Market Size by Country (2021-2026)
- 10.4 South America AI Drug Design Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa AI Drug Design Market Size (2021-2032)
- 11.2 Middle East & Africa AI Drug Design Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa AI Drug Design Market Size by Country (2021-2026)
- 11.4 Middle East & Africa AI Drug Design Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Exscientia
- 12.1.1 Exscientia Company Information
- 12.1.2 Exscientia Business Overview
- 12.1.3 Exscientia Revenue in AI Drug Design Business (2021-2026)
- 12.1.4 Exscientia AI Drug Design Product Portfolio
- 12.1.5 Exscientia Recent Developments
- 12.2 PathAI
- 12.2.1 PathAI Company Information
- 12.2.2 PathAI Business Overview
- 12.2.3 PathAI Revenue in AI Drug Design Business (2021-2026)
- 12.2.4 PathAI AI Drug Design Product Portfolio
- 12.2.5 PathAI Recent Developments
- 12.3 Tempus
- 12.3.1 Tempus Company Information
- 12.3.2 Tempus Business Overview
- 12.3.3 Tempus Revenue in AI Drug Design Business (2021-2026)
- 12.3.4 Tempus AI Drug Design Product Portfolio
- 12.3.5 Tempus Recent Developments
- 12.4 Aria Pharmaceuticals
- 12.4.1 Aria Pharmaceuticals Company Information
- 12.4.2 Aria Pharmaceuticals Business Overview
- 12.4.3 Aria Pharmaceuticals Revenue in AI Drug Design Business (2021-2026)
- 12.4.4 Aria Pharmaceuticals AI Drug Design Product Portfolio
- 12.4.5 Aria Pharmaceuticals Recent Developments
- 12.5 BenchSci
- 12.5.1 BenchSci Company Information
- 12.5.2 BenchSci Business Overview
- 12.5.3 BenchSci Revenue in AI Drug Design Business (2021-2026)
- 12.5.4 BenchSci AI Drug Design Product Portfolio
- 12.5.5 BenchSci Recent Developments
- 12.6 Antidote
- 12.6.1 Antidote Company Information
- 12.6.2 Antidote Business Overview
- 12.6.3 Antidote Revenue in AI Drug Design Business (2021-2026)
- 12.6.4 Antidote AI Drug Design Product Portfolio
- 12.6.5 Antidote Recent Developments
- 12.7 AiCure
- 12.7.1 AiCure Company Information
- 12.7.2 AiCure Business Overview
- 12.7.3 AiCure Revenue in AI Drug Design Business (2021-2026)
- 12.7.4 AiCure AI Drug Design Product Portfolio
- 12.7.5 AiCure Recent Developments
- 12.8 Atomwise
- 12.8.1 Atomwise Company Information
- 12.8.2 Atomwise Business Overview
- 12.8.3 Atomwise Revenue in AI Drug Design Business (2021-2026)
- 12.8.4 Atomwise AI Drug Design Product Portfolio
- 12.8.5 Atomwise Recent Developments
- 12.9 Envisagenics
- 12.9.1 Envisagenics Company Information
- 12.9.2 Envisagenics Business Overview
- 12.9.3 Envisagenics Revenue in AI Drug Design Business (2021-2026)
- 12.9.4 Envisagenics AI Drug Design Product Portfolio
- 12.9.5 Envisagenics Recent Developments
- 12.10 Sherlock
- 12.10.1 Sherlock Company Information
- 12.10.2 Sherlock Business Overview
- 12.10.3 Sherlock Revenue in AI Drug Design Business (2021-2026)
- 12.10.4 Sherlock AI Drug Design Product Portfolio
- 12.10.5 Sherlock Recent Developments
- 12.11 Deep Genomics
- 12.11.1 Deep Genomics Company Information
- 12.11.2 Deep Genomics Business Overview
- 12.11.3 Deep Genomics Revenue in AI Drug Design Business (2021-2026)
- 12.11.4 Deep Genomics AI Drug Design Product Portfolio
- 12.11.5 Deep Genomics Recent Developments
- 12.12 Benevolent
- 12.12.1 Benevolent Company Information
- 12.12.2 Benevolent Business Overview
- 12.12.3 Benevolent Revenue in AI Drug Design Business (2021-2026)
- 12.12.4 Benevolent AI Drug Design Product Portfolio
- 12.12.5 Benevolent Recent Developments
- 12.13 Iktos
- 12.13.1 Iktos Company Information
- 12.13.2 Iktos Business Overview
- 12.13.3 Iktos Revenue in AI Drug Design Business (2021-2026)
- 12.13.4 Iktos AI Drug Design Product Portfolio
- 12.13.5 Iktos Recent Developments
- 12.14 AlmirallShare
- 12.14.1 AlmirallShare Company Information
- 12.14.2 AlmirallShare Business Overview
- 12.14.3 AlmirallShare Revenue in AI Drug Design Business (2021-2026)
- 12.14.4 AlmirallShare AI Drug Design Product Portfolio
- 12.14.5 AlmirallShare Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst